The lessons learned in developing companion diagnostics (CDx) for cancer – which accounts for all but one FDA-approved in vitro CDx device – are beginning to resonate in other fields, including autoimmune, cardiovascular (CVD), central nervous system and infectious diseases. Read More

NEW DELHI – Medium- to large-sized Indian pharmaceutical companies are aggressively pursuing international acquisitions to strengthen their market presence across developed and emerging markets, and to gain a foothold in markets they are currently not strong in, according to new analysis by the Associated Chambers of Commerce and Industry of India (Assocham) and Hyderabad-based Sathguru Management Consultants. Read More

Syntimmune Inc., a company developing a portfolio of treatments for immunoglobulin G-mediated autoimmune diseases based on neonatal Fc receptor (FcRn) biology, has triggered a $10 million tranche of the company's committed $26 million series A financing. Read More

HONG KONG – The findings of a new study by Chinese researchers have led to the discovery of a new means of increasing the anticancer activity of the immune system's killer T cells by modifying cholesterol metabolism, which could be used to complement other current cancer immunotherapies, such as immune checkpoint blockade. Read More

"We're not done," Zymeworks Inc. CEO Ali Tehrani told BioWorld Today as the firm disclosed its takeover of Kairos Therapeutics Inc. to bring aboard a next-generation antibody-drug conjugate (ADC) technology. Read More

Sequenom Inc., of San Diego, appealed to the Supreme Court Monday to narrow the sweeping application of its decision in Mayo Collaborative Services v. Prometheus Laboratories that has jeopardized the patentability of diagnostic method patent claims involving a naturally occurring phenomenon. Read More

Hutchison China Meditech Ltd. (Chi-Med), of London, said it closed its U.S. public offering of American depositary shares (ADS), raising gross proceeds of $101.25 million through the sale of 7.5 million ADSs at $13.50 apiece. Read More

Amicus Therapeutics Inc., of Cranbury, N.J., initiated a reimbursed expanded access program to provide Fabry patients who have amenable mutations with access to migalastat in certain territories where reimbursement can be secured prior to marketing authorization and commercial availability. Read More

Ritter Pharmaceuticals Inc., of Los Angeles, said it dosed the first patient in its phase IIb/III trial of RP-G28 for the treatment of lactose intolerance. Read More